Details of the Drug

General Information of Drug (ID: DMCNL7Z)

Drug Name
MT-3724
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Phase 2 [1]
Non-hodgkin lymphoma 2B33.5 Phase 2 [1]
B-cell chronic lymphocytic leukaemia 2A82.00 Phase 1 [2]
B-cell lymphoma 2A86 Phase 1 [3]
B-cell non-hodgkin lymphoma 2B33.5 Phase 1 [2]
Drug Type
Recombinant?protein
Cross-matching ID
TTD ID
DZNH43
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03488251) PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of Molecular Templates.